Advances in Predictive Biomarkers for Immune Checkpoint Inhibitors in Lung Cancer: Why, Who, and How

Review this program to get up to date on the latest data informing optimal integration of immunotherapy biomarkers into the management of patients with lung cancer including an on-demand Webcast capturing discussion by medical oncology and pathology experts from a symposium at the 2019 Clinical Pathology meeting and downloadable slidesets.

Share

Program Content

No activities added yet

No activities added yet

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Bristol Myers Squibb

Genentech TEXT Only

Merck Sharp & Dohme Corp.